- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05717491
Study of Diabetes' Risk Factors and Accelerated Aging According to Socio-economic Status in a Population From the North of France (PREVENDIAB)
Populations in precarious situations or with low socio-economic status have an increased risk of diabetes and accelerated aging. According to the population studied, the elements that can explain these health inequalities are not unequivocal and remain poorly known.
The north of France, particularly affected by socio-economic disparities, has a prevalence of diabetes among the highest in metropolitan France. This is why investigators want to study the clinical, biological, social and behavioural risk factors of the entry into diabetes and accelerated aging among a large population in the North of France.
This study aims to characterize the population (among which a majority (55%) suffers from precarious conditions) who come to carry out their health examination at the Pasteur Institute in Lille in order to study the risk factors to better explain these health inequalities.
This research consists of a main descriptive observational, cross-sectional study carried out on 2233 volunteers (main group) over 18 months, and a complementary analytical case-control study that will be offered to 216 participants (sub-group).
Study Overview
Status
Conditions
Detailed Description
Primary Objective : Assessment of Prevalence of Prediabetes and Diabetes by Socio-Economic Status
Primary efficacy endpoint : Fasting glucose value based on EPICES score :
Glycemia:
- Normal: fasting glucose ≤ 1g/l
- Prediabetes: fasting glucose >1 g/l and ≤1.25 g/l
- Diabetes: fasting glucose >1.25 g/l
EPICES score: quintiles of score distribution (Q1 to Q5)
Secondary Objectives specific to the main group:
- Characterize the population and analyze the risk factors (clinical, biological, socio-economic and behavioural) of diabetes and prediabetes in this population.
- Study the level of biological ageing and factors associated with accelerated ageing.
- Estimate the risk of (pre)diabetes and accelerated aging based on socio-economic profile.
Secondary Objectives specific to the sub-group:
- Assess the impact of economic, social and cultural capital on health in terms of diabetes and accelerated aging.
- Analyze the effect on diabetes and accelerated aging of the exposures assessed: body composition, physical activity, arterial rigidity, cognitive status, psychiatric disorders, fragility, pain.
Secondary endpoints specific to the main group: :
Prevalence ratio of diabetes and prediabetes calculated for:
- Clinical, paraclinical parameters (Oral examination, Muscle strength,Advanced glycation products) and anthropometric parameters (medical history, height, weight, BMI, Waist and hip circumference, Neck circumference, body composition measurement, Systolic and diastolic blood pressure, Unipedal stance test).
- Biological (blood and genetic).
- Behavioural/environmental predictors: (socio-economic status, physical activity(RICCI GAGNON), diet(HDI), quality of life (MQLI), stress-anxiety(PSS), toxic habits, fragility(FRIED) ).
Assessment of the level of ageing
- Biological Aging Marker: DNAmPhenoAge (DNA methylation phenotypic age)
- Accelerated ageing: age regression DNAmPhenoAge on chronological age
- Analysis of age-related parameters (inflammatory, renal, hormonal, body composition measurement, fragility, advanced glycation products, muscle strength) and correlation with methylation rate and DNAmPhenoAge.
Prevalence ratio of (pre)diabetes and accelerated aging according to socio-economic status
- Evaluation of (pre)diabetes: fasting blood sugar
- Accelerated Aging Assessment: DNAm PhenoAge
- Social Status Assessment: EPICES Q1 to Q5 Score
- Assessment of economic status: Income level
Secondary endpoints specific to the subgroup:
Risk (OR) of (pre)diabetes and accelerated aging according to social, economic, cultural and marital status
- Evaluation of (pre)diabetes: fasting blood sugar
- Accelerated Aging Assessment: DNAmPhenoAge
Socio-economic and cultural criteria
- Social status (EPICES score)
- Economic status (income)
- Cultural status (semi-directive interview)
- Professional status (educational level, socio-professional category, marital status)
Risk (OR) of (pre)diabetes and accelerated aging for assessed exposures:
- Evaluation of (pre)diabetes: fasting blood sugar
- Accelerated Aging Assessment: DNAmPhenoAge
Exposure Assessment
- Arterial Stiffness Index
- Body composition (mineral density, lean mass, fat mass) (DEXA test)
- Insomnia Severity Index (ISI)
- Cognitive Status (MOCA)
- Physical Activity (GPAQ Questionnaire)
- Alcohol consumption (FACE)
- Psychiatric disorders (MINI)
- Fragility (REFS score)
- Pain Scale (EVA)
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Hauts De France
-
Lille, Hauts De France, France, 59019
- Institut Pasteur de Lille
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Populations in precarious situations or with a low socioeconomic level have an increased risk of entering diabetes and aging accelerated. Depending on the populations studied, the elements that could explain these health inequalities are not unequivocal and are still badly known.
The Hauts-de-France region, particularly affected by disparities socio-economic, has one of the most prevalent diabetes high in the metropolis. This is why it's important to study the factors clinical, biological, social and behavioral risks of entry in diabetes and accelerated aging in a large population of North of France.
This study aims to characterize the population of the Centre's consultants of Health Examinations at the Institut Pasteur de Lille, of which a majority (55%) suffers from precarious conditions, in order to study the risk factors to better explain these health inequalities.
Description
Inclusion Criteria:
- Adult, male or female
- Consultant for the health prevention examination at the Examination Centre of Health of the Institut Pasteur of Lille
- Available to follow the constraints generated by the study
- Signature of the informed consent
- Status of insured person in France
Exclusion Criteria:
- Participation in another clinical study or in a period of exclusion from another study
- Adult deprived of liberty or under judicial protection
- Impediment to give the free and informed consent (understanding, persons under guardianship/curators, etc.)
- Incompatible scheduling
- Other reason (state of health or concomitant treatments,...) considered by the principal investigator or a qualified co-investigator not compatible with the proper conduct of the clinical study
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Main group
Cross-sectional study
|
Biological analysis, Physical examination and questionnaires will be performed for all patients of the main group.
|
|
Sub group
Case control study
|
In addition to exams for the main group, there will be 2 additional examinations (bone densitometry and arterial stiffness) for the patients of the subgroup and others questionnaires.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fasting glucose value according to the level of precariousness
Time Frame: Day 0
|
Glycemia in g/L Level of precariousness given by EPICES score
|
Day 0
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence ratio of (pre)diabetes calculated for clinical, biological and behavioral/environmental explanatory variables
Time Frame: Day 0
|
In %
|
Day 0
|
|
Assessment of the level of accelerated ageing (DNAmPhenoAge)
Time Frame: Day 0
|
In units of years
|
Day 0
|
|
Prevalence ratio of (pre) diabetes and accelerated aging according to the socio-economic status
Time Frame: Day 0
|
In %
|
Day 0
|
|
Risk (odds Ratio) of (pre) diabetes and accelerated aging according to social, economic, cultural and professional status
Time Frame: Until Day 90
|
Without units
|
Until Day 90
|
|
Risk (odds Ratio) of (pre) diabetes and accelerated aging for assessed exposures
Time Frame: Until Day 90
|
Without units
|
Until Day 90
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Philippe Dr FROGUEL, PhD, PRECIDIAB
- Study Director: Matthias Mr VANDESQUILLE, PhD, PRECIDIAB
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-A01727-34
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of North Carolina, Chapel HillAmerican Diabetes AssociationNot yet recruitingType 2 Diabetes Mellitus (T2DM) | Diabetes (DM) | Insulin Dependent Diabetes | Type 1 Diabetes (T1D) | Diabetes Education | Diabetes Care | Diabetes (Insulin-requiring, Type 1 or Type 2)United States
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Steno Diabetes Center CopenhagenNot yet recruitingDiabetes | Diabetes Type 1 | Diabetes Type 2 | Digital Health | Diabetes Care | Remote Patient MonitoringDenmark
-
DiappyMedSanoiaRecruitingDiabetes Type 1 | Pancreatogenous Diabetes | Diabetes Type 2 on InsulinFrance
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
Clinical Trials on Biological analysis, Physical examination and Questionnaires
-
Institut Pasteur de LilleNot yet recruiting
-
University of RochesterCompletedPelvic Organ ProlapseUnited States
-
Bozyaka Training and Research HospitalActive, not recruiting
-
Ege UniversityCompletedFibromyalgia | Coronavirus Disease 2019 PandemicTurkey
-
McGill University Health Centre/Research Institute...Rambam Health Care Campus; Louise and Alan Edwards FoundationActive, not recruiting
-
University Hospital, EssenCharite University, Berlin, Germany; University Hospital Muenster; University... and other collaboratorsRecruitingGlioblastoma (GBM)Germany
-
Mayo ClinicCompleted
-
Bozyaka Training and Research HospitalEnrolling by invitationNeuropathic Pain | Balance; Distorted | Postural StabilityTurkey
-
Xuanwu Hospital, BeijingNot yet recruitingLumbar Disc Herniation | Lumbar Spinal Stenosis | Degenerative Scoliosis | Adult Spinal Deformity | Cervical Spondylosis With Myelopathy | Sagittal Deformity | Sagittal Imbalance | Coronal Vertical AxisChina
-
Centre Hospitalier Universitaire de NīmesCompleted